|
|
|
| Retrospective analysis of the CsA concentration monitoring strategies of 104 children with aplastic anemia |
| CHENG Xiaoling1 MA Jie2 CHEN Zhenping2 SHI Qiang1 TIAN Chao1 WU Runhui2 WANG Xiaoling1 |
1.Department of Pharmacy, Children′s National Medical Center Beijing Children′s Hospital, Capital Medical University, Beijing 100045, China;
2.State Key Laboratory, Hematology Oncology Center, Children′s National Medical Center Beijing Children′s Hospital, Capital Medical University, Beijing 100045, China |
|
|
|
Abstract Objective To analyze the factors influencing the blood concentration of cyclosporine A (CsA) in treatment of children with aplastic anemia (AA), and provide reference for the therapeutic drug monitoring of CsA and individualized medication. Methods Clinical data of 104 children with non-severe AA treated in Beijing Children′s Hospital, Capital Medical University from January 2014 to December 2017 were enrolled in this study, including gender, age, weight, clinical diagnosis, CsA blood concentration, usage and dosage, combined medication, and adverse drug reaction, et al. The results were analyzed statically. Results Among the first time of therapeutic drug monitoring children, only 18% (19 cases) were within the therapeutic window. Constituent ratios of children with dose titration once, twice, three times, four times, equal or more than five times were 21% (22 cases), 20% (21 cases), 13% (14 cases), 9% (8 cases), 19% (20 cases) respectively. The median times of therapeutic drug monitoring was 3 times (1-13 times). There were 9 cases treated combined with Berberine and 1 case was treated with Voriconazole, and the blood concentration reached the therapeutic window after the combination of drugs of 104 cases. Children with adverse reattioms were coun ted among the 104 cases, and there were 9.6% (10 cases) simply appearing hairy adverse reaction, 4.8% (5 cases) simply appearing gingiva hyperplasia, 11.6% (12 cases) appearing the two, 1.9% (2 cases) with blood pressure increasing, 1.9% (2 cases) with abnormal liver enzymes. Conclusion The pharmacokinetic parameters of CsA vary greatly among individuals, and the concentration of CsA blood drug is affected by many factors. Especially for children, timely monitoring the concentration of CsA blood drug of children with AA can guide their individualized medication rationally. It is imperative to find ways to optimize and improve the concentration of CsA.
|
|
|
|
|
|
[1] Young NS，Bacigalupo A，Marsh JC. Aplastic anemia: pathophysiology and treatment [J]. Biol Blood Marrow Transplant，2010，16（1）：119-125.
[2] Guinan EC. Acquired aplastic anemia in childhood [J]. Hematol Oncol Clin North Am，2009，23（2）：171-191.
[3] Korthof ET，Békássy AN，Hussein AA. Management of acquired aplastic anemia in children [J]. Bone Marrow Transplant，2013，48（2）：191-195.
[4] 中华医学会儿科学分会血液学组.儿童获得性再生障碍性贫血诊疗建议[J].中华儿科杂志，2014，52（2）：103-106.
[5] Young NS，Barrett AJ. The treatment of severe acquired aplastic anemia [J]. Blood，1995，85（2）：3367-3377.
[6] Rosenfeld S，Follmann D，Nunez O，et al. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome [J]. JAMA，2003，289（9）：1130-1135.
[7] Lawlor ER，Anderson RA，Davis JH，et al. Immunosuppressive therapy：a potential alternative to bone marrow transplantation as initial therapy for acquired severe aplastic anemia in childhood?[J]. J Pediatr Hematol Oncol，1997，19（2）：115-123.
[8] 付蓉.再生障碍性贫血诊断与治疗中国专家共识（2017年版）[J].中华血液学杂志，2017（1）：1-5.
[9] Marsh JC. Management of acquired aplastic anaemia [J]. Blood Rev，2005，19（3）：143-151.
[10] Barone A，Lucarelli A，Onofrillo D. Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association （AIEOP）[J]. J Pediatr Hematol Oncol，1997，19（2）：115-123.
[11] 刘石带，罗美娟，黄靓.10 606例次环孢素治疗药物监测结果分析[J].海峡药学，2014，26（4）：92-94.
[12] Denisov IG，Grinkova YV，Baylon JL，et al. Mechanism of drug-drug interactions mediated by human cytochrome P450 CYP3A4 monomer [J]. Biochemistry，2015，54（13）：2227-2239.
[13] 曲婷，乔宏艳，段丽娟，等.影响骨髓移植术后环孢素A血药浓度的相关因素分析[J].现代生物医学进展，2014， 14（35）：6889-6892.
[14] 陈国宁，祁峰.676例环孢素A血药浓度影响因素分析[J].黑龙江医药，2016，29（6）：1080-1084.
[15] 余爱荣，吴笑春，辛华雯，等.盐酸黄连素对环孢素A增效作用的药物动力学研究[J]．华南国防医学杂志，2002， 17（1）：12-15.
[16] 李馨，吴笑春，辛华雯，等.盐酸黄连素对肾移植受者环孢素A增效作用的临床药代动力学研究[J].中国临床药理学杂志，2001，17（6）：448-450.
[17] 李馨，吴笑春，辛华雯，等.盐酸小檗碱对肾移植受者环孢素A血浓的影响[J].中华器官移植杂志，2001，22（4）：209-211.
[18] Park SJ，Song IS，Kang SW. Pharmacokinetic effect of voriconazole on cyclosporine in the treatment of aspergillosis after renal transplantation [J]. Clin Nephrol，2012，78（5）：412-418.
[19] Edwards DJ，Fitzsimmons ME，Schuetz EG，et al. 6，7，-Dihydrroxy-beramottin in grapefruit juice and sexille orange juice：effect on cyclo-porine disposition，enterocyte CYP3A4，and P-glocoprotein [J]. Clin Pharmacol Ther，1999，65（3）：237-244.
[20] Masri MA．The mosaic of immunosupprissive drugs [J]. Molecular Im-munology，2003，39（17/18）：1073-1075.
[21] Singh D，Kiberd B，Belisky P，et al. Therapeutic monitoring of cyclosporine in kidney transplantation：the halifax experience [J]. Trsns plant Proo，2004，36（2）：414-419.
[22] 卢静，张瑞雯，力弘.环孢素不良反应发生机制和对策[J].中国临床药学杂志，2005（4）：260-262. |
|
|
|
